|
1
|
Furuya-Kanamori L, Sedrakyan A, Onitilo
AA, Bagheri N, Glasziou P and Doi SAR: Differentiated thyroid
cancer: Millions spent with no tangible gain? Endocr Relat Cancer.
25:51–57. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Alzahrani AS, Alomar H and Alzahrani N:
Thyroid cancer in Saudi Arabia: A histopathological and outcome
study. Int J Endocrinol. 2017(8423147)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fagin JA and Wells SA Jr: Biologic and
clinical perspectives on thyroid cancer. N Engl J Med.
375:1054–1067. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Grieco M, Santoro M, Berlingieri MT,
Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G,
Fusco A and Vecchio G: PTC is a novel rearranged form of the ret
proto-oncogene and is frequently detected in vivo in human thyroid
papillary carcinomas. Cell. 60:557–563. 1990.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nikiforova MN, Biddinger PW, Caudill CM,
Kroll TG and Nikiforov YE: PAX8-PPARgamma rearrangement in thyroid
tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol.
26:1016–1023. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Murugan AK, Dong J, Xie J and Xing M:
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid
cancers. Endocr Pathol. 22:97–102. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cancer Genome Atlas Research Network.
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Murugan AK, Qasem E, Al-Hindi H, Shi Y and
Alzahrani AS: Classical V600E and other non-hotspot BRAF mutations
in adult differentiated thyroid cancer. J Transl Med.
14(204)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Murugan AK, Qasem E, Al-Hindi H and
Alzahrani AS: GPCR-mediated PI3K pathway mutations in pediatric and
adult thyroid cancer. Oncotarget. 10:4107–4124. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Melo M, da Rocha AG, Vinagre J, Batista R,
Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, et
al: TERT promoter mutations are a major indicator of poor outcome
in differentiated thyroid carcinomas. J Clin Endocrinol Metab.
99:E754–E765. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT
promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer. 20:603–610. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Xing M, Liu R, Liu X, Murugan AK, Zhu G,
Zeiger MA, Pai S and Bishop J: BRAF V600E and TERT promoter
mutations cooperatively identify the most aggressive papillary
thyroid cancer with highest recurrence. J Clin Oncol. 32:2718–2726.
2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen Y, Takita J, Choi YL, Kato M, Ohira
M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, et al:
Oncogenic mutations of ALK kinase in neuroblastoma. Nature.
455:971–974. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Palavalli LH, Prickett TD, Wunderlich JR,
Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC,
Agrawal NS, et al: Analysis of the matrix metalloproteinase family
reveals that MMP8 is often mutated in melanoma. Nat Genet.
41:518–520. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Morris SW, Kirstein MN, Valentine MB,
Dittmer KG, Shapiro DN, Saltman DL and Look AT: Fusion of a kinase
gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's
lymphoma. Science. 263:1281–1284. 1994.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Geisbrecht BV and Gould SJ: The human PICD
gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent
isocitrate dehydrogenase. J Biol Chem. 274:30527–30533.
1999.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Quintero-Fabián S, Arreola R,
Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V,
Lara-Riegos J, Ramírez-Camacho MA and Alvarez-Sánchez ME: Role of
matrix metalloproteinases in angiogenesis and cancer. Front Oncol.
9(1370)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Murugan AK and Xing M: Anaplastic thyroid
cancers harbor novel oncogenic mutations of the ALK gene. Cancer
Res. 71:4403–4411. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Latteyer S, Tiedje V, König K, Ting S,
Heukamp LC, Meder L, Schmid KW, Führer D and Moeller LC: Targeted
next-generation sequencing for TP53, RAS, BRAF, ALK and NF1
mutations in anaplastic thyroid cancer. Endocrine. 54:733–741.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Murugan AK, Bojdani E and Xing M:
Identification and functional characterization of isocitrate
dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys
Res Commun. 393:555–559. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hemerly JP, Bastos AU and Cerutti JM:
Identification of several novel non-p.R132 IDH1 variants in thyroid
carcinomas. Eur J Endocrinol. 163:747–755. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Murugan AK, Humudh EA, Qasem E, Al-Hindi
H, Almohanna M, Hassan ZK and Alzahrani AS: Absence of somatic
mutations of the mTOR gene in differentiated thyroid cancer. Meta
Gene. 6:69–71. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Landa I, Ibrahimpasic T, Boucai L, Sinha
R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP,
Xu B, et al: Genomic and transcriptomic hallmarks of poorly
differentiated and anaplastic thyroid cancers. J Clin Invest.
126:1052–1066. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tripathi P, Hong X, Caruso D, Gao P and
Wang X: Genetic determinants in the development of sensitization to
environmental allergens in early childhood. Immun Inflamm Dis.
2:193–204. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kader AK, Liu J, Shao L, Dinney CP, Lin J,
Wang Y, Gu J, Grossman HB and Wu X: Matrix metalloproteinase
polymorphisms are associated with bladder cancer invasiveness. Clin
Cancer Res. 13:2614–2620. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lin Y, Liu J, Jin L and Jiang Y:
Polymorphisms in matrix metalloproteinases 2, 3, and 8 increase
recurrence and mortality risk by regulating enzyme activity in
gastric adenocarcinoma. Oncotarget. 8:105971–105983.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Nan H, Niu T, Hunter DJ and Han J:
Missense polymorphisms in matrix metalloproteinase genes and skin
cancer risk. Cancer Epidemiol Biomarkers Prev. 17:3551–3557.
2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang LF, Zhu LJ and Zhang W, Yuan W, Song
NH, Zuo L, Mi YY, Wang ZJ and Zhang W: MMP-8 C-799 T, Lys460Thr,
and Lys87Glu variants are not related to risk of cancer. BMC Med
Genet. 20(162)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Juurikka K, Butler GS, Salo T, Nyberg P
and Åström P: The role of MMP8 in cancer: A systematic review. Int
J Mol Sci. 20(4506)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Murugan AK, Munirajan AK and Tsuchida N:
Ras oncogenes in oral cancer: The past 20 years. Oral Oncol.
48:383–392. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zou M, Baitei EY, Alzahrani AS, BinHumaid
FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS,
RET/PTC, or BRAF mutations in advanced stage of papillary thyroid
carcinoma. Thyroid. 24:1256–1266. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Roskoski R Jr: Properties of FDA-approved
small molecule protein kinase inhibitors: A 2021 update. Pharmacol
Res. 165(105463)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Naito T, Shiraishi H and Fujiwara Y:
Brigatinib and lorlatinib: Their effect on ALK inhibitors in NSCLC
focusing on resistant mutations and central nervous system
metastases. Jpn J Clin Oncol. 51:37–44. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Platten M, Bunse L, Wick A, Bunse T, Le
Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, et al: A
vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature.
592:463–468. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Murugan AK, Al-Amr A, Al-Ansari MM,
Manogaran PS, Al-Hindi H and Alzahrani AS: Single nucleotide
polymorphisms in matrix metalloproteinase 2 (MMP2) enhance
BRAFV600E mutation-mediated oncogenicity and invasiveness of
papillary thyroid cancer cells. Endocr Relat Cancer. 28:273–289.
2021.PubMed/NCBI View Article : Google Scholar
|
